INDOCO REMEDIES LTD.

Indoco Remedies Ltd announced that its Board of Directors, in a meeting held on July 28, 2026, approved the re-appointment of Ms. Aditi Panandikar as Managing Director for a term of 5 years, effective February 15, 2027, to February 14, 2032. This reappointment is subject to shareholder approval at the upcoming 79th Annual General Meeting. Additionally, Mr. Sudhir Kadam has been appointed as Senior Management Personnel, designated as Sr. Vice President (Human Capital), effective July 28, 2026. Ms. Panandikar, daughter of Chairman Mr. Suresh G Kare, brings over 30 years of experience in various functions. Mr. Kadam is a Human Resource professional with 30 years of experience.

Indoco Remedies Ltd announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board of Directors approved these results along with a Limited Review Report from statutory auditors M/s. Gokhale & Sathe, Chartered Accountants, who issued an unmodified opinion. The company reported an exceptional item gain of ₹9,734 Lakhs from the slump sale of its Ophthalmic Business Division to Sunways (India) Private Limited. The Board meeting commenced at 10:45 a.m. and concluded at 11:45 a.m. on July 28, 2026.

Indoco Remedies posted a consolidated Q1 FY27 net profit of ₹65.4 Cr versus a ₹36.4 Cr loss a year ago, but the swing is optical: the entire profit comes from a ₹97.3 Cr exceptional gain on the completed slump sale of its Ophthalmic Division to Sunways (India). Strip the one-off out and the group was still loss-making, with a pre-exceptional loss before tax of ₹19.6 Cr — narrower than the ₹36.7 Cr year-ago loss, but not a genuine operating turnaround. On an adjusted basis this is a narrowing loss, not the +₹65 Cr print the headline shows. Revenue was the one solid number: consolidated operating income rose 6.3% YoY to ₹467.5 Cr (−1.7% QoQ off the seasonally stronger March quarter), and standalone EBITDA margin expanded sharply to 10.3% from 3.8% a year earlier — a real operational recovery that management attributed to the resilient domestic formulations business. The growth mix, however, inverted the last-call guidance. Management had guided to 'continued strong growth in international formulations' with domestic merely tracking the IPM; the actual print was the reverse — India net sales jumped 12.2% YoY to ₹311.8 Cr while outside-India revenue was essentially flat at ₹154.5 Cr. The margin-improvement pillar of guidance was met, but the international-growth pillar was not, and MD Aditi Panandikar's own commentary conceded international and API businesses made only 'steady progress.' Below EBITDA, high finance costs (₹28.3 Cr) and depreciation (₹34.5 Cr) still drag the group into a pre-exceptional loss, and the auditors flagged a going-concern uncertainty on US arm FPP Holding LLC (negative net worth ₹38.2 Cr). No Q1-specific street consensus exists for this small-cap; against the SMIFS FY27E EBITDA-margin bar of ~10.9%, the ~10.3% standalone print lands roughly in line. The Ophthalmic-sale proceeds set up the flagged ~₹140 Cr FY27 debt-reduction plan; the real test next quarter is whether the core can turn profitable without one-offs.

Indoco Remedies Ltd has announced that its Board of Directors will convene on July 28, 2026. The primary agenda item is to consider and approve the Unaudited Standalone and Consolidated Financial Results for the first quarter ended June 30, 2026. In line with SEBI regulations, the trading window for designated persons and their immediate relatives will remain closed until 48 hours after the declaration of these financial results, extending up to July 30, 2026.

Indoco Remedies Ltd has announced the closure of its trading window for dealing in equity shares. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The window will be shut from July 1, 2026, until 48 hours after the declaration of the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. During this period, all designated persons and their immediate relatives are prohibited from trading in the company's shares. The date for the board meeting to approve these financial results will be communicated separately.

Indoco Remedies Ltd. announced that its manufacturing facility for solid oral dosage form (Plant I) in Goa has successfully passed an audit by the Malta Medicines Authority. The inspection took place from November 19 to November 24, 2025. Following the audit, the facility received EU GMP certification, confirming compliance with Good Manufacturing Practice requirements as per EC Directive. Ms. Aditi Panandikar, Managing Director, stated that this approval reinforces the company's commitment to quality healthcare delivery worldwide. Indoco Remedies is an integrated pharmaceutical company with a global presence, 10 manufacturing facilities, and approvals from major regulatory authorities like USFDA and UK-MHRA.

Indoco Remedies Ltd. announced that its Oral Solid Dosage (OSD) manufacturing facility (Plant III) located at Baddi, Himachal Pradesh, has received EU GMP certification from the German Health Authority (Berlin). The inspection was conducted from April 22 to April 27, 2026. This certification confirms that the facility adheres to the Good Manufacturing Practice requirements as outlined in the EC Directive. Ms. Aditi Panandikar, Managing Director, highlighted that this certification underscores the company's dedication to delivering high-quality products to patients worldwide. Indoco is a fully integrated pharmaceutical company with a strong global presence and multiple manufacturing facilities approved by various regulatory authorities, including USFDA and UK-MHRA.

Indoco Remedies Ltd. has completed the transfer of its Ophthalmic Division to Sunways (India) Private Limited as a going concern on a slump sale basis. This transfer, effective May 18, 2026, follows the Agreement to Transfer Business (ATB) and fulfills all conditions precedent. The Ophthalmic Division includes operations in India, Benin, Burkina Faso, Ivory Coast, Mali, Niger, Mauritania, Senegal, Cameroon, Congo, Gabon, Kenya, Botswana, Tanzania, Zambia, Zimbabwe, and Namibia.

Indoco Remedies Ltd. announced the demise of Dr. Anand Nadkarni (DIN : 06881461), a Non-Executive Director of the company, on Friday, May 15, 2026. The company acknowledged Dr. Nadkarni's contributions and expressed condolences to his family. Details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 were enclosed.

Indoco Remedies Ltd. announced that its manufacturing facility for solid oral dosage form (Unit I) in Baddi has received EU GMP certification from the Malta Medicines Authority after an inspection conducted from January 29, 2026, to February 3, 2026. The certification confirms compliance with Good Manufacturing Practice requirements as per the EC Directive. This approval reflects Indoco's commitment to quality and adherence to global regulatory standards.